Tami D John, Gabriela Maron, Allistair Abraham, Alice Bertaina, Senthil Velan Bhoopalan, Alan Bidgoli, Carmem Bonfim, Zane Coleman, Amy DeZern, Jingjing Li, Chrystal Louis, Joseph Oved, Mara Pavel-Dinu, Duncan Purtill, Annalisa Ruggeri, Athena Russell, Robert Wynn, Jaap Jan Boelens, Susan Prockop, Akshay Sharma
There is lack of guidance for immune monitoring and infection prevention after administration of ex vivo genetically modified hematopoietic stem cell therapies (GMHSCT). We reviewed current infection prevention practices as reported by providers experienced with GMHSCTs across North America and Europe, and assessed potential immunologic compromise associated with the therapeutic process of GMHSCTs described to date. Based on these assessments, and with consensus from members of the International Society for Cell & Gene Therapy (ISCT) Stem Cell Engineering Committee, we propose risk-adapted recommendations for immune monitoring, infection surveillance and prophylaxis, and revaccination after receipt of GMHSCTs...
February 20, 2024: Cytotherapy